Speakers

Mani Mudaliar is Director of Quantitative Biomarkers at Recursion, where he leads strategic efforts to advance the development, validation, and deployment of biomarker platforms that support Recursion’s mission to industrialise drug discovery through large-scale biology and cutting-edge machine learning. In this senior role, he works at the interface of computational modelling, high-dimensional biology, and translational science, ensuring that quantitative biomarker strategies meaningfully accelerate therapeutic development across multiple disease areas. 

Prior to the merger of Recursion and Exscientia—uniting two major innovators in AI-enabled drug discovery—Mani served as Director of Quantitative Biomarkers at Exscientia. He was previously Director of Target Discovery at the company, where he played a central role in building and refining discovery pipelines driven by functional genomics, multimodal data integration, and proprietary AI systems. His work guided programme selection, illuminated disease mechanisms, and enabled data-rich decision-making across early discovery. 

Before joining Exscientia, Mani was Head of Bioinformatics at Summit Therapeutics, where he oversaw computational strategy and analytic infrastructure across R&D programmes. Earlier, as a Principal Scientist in Bioinformatics at Cerevance, he contributed to the development of CNS-focused discovery approaches rooted in advanced transcriptomics, single-cell technologies, and molecular profiling from human post-mortem tissues. 

Alongside his industry leadership roles, Mani held a five-year appointment as Honorary Research Fellow in Immunology and Bioinformatics at the University of Glasgow, contributing to academic collaborations exploring immune regulation, host–pathogen interactions, and computational methods for understanding complex biological systems.